PharmEasy unlisted share price

Price history

About

API Holdings Limited is the company behind PharmEasy. The group sells medicines and healthcare products across India through two main routes: a digital marketplace for consumers and a distribution network that supplies local chemists, hospitals and other institutions. It also earns service revenue, mostly from diagnostics through Thyrocare Technologies, which is a listed step-down subsidiary. The numbers below are consolidated, as printed in the FY26 annual report (year ended 31 March 2026). Revenue from operations was INR 66,185 million, up from INR 58,722 million a year earlier, a rise of 12.7%. Of this, sale of products was INR 56,700 million and sale of services was INR 9,413 million. The chemist and institution distribution business, called Retailio 1P, brought in INR 38,579 million. The hospital supply business, Aknamed, brought in INR 8,470 million. The group is still loss making, but the gap has narrowed. Loss after tax was INR 5,203 million in FY26 against INR 15,724 million in FY25. EBITDA before exceptional items and ESOP expense turned positive at INR 999 million, or 1.5% of revenue, from a negative INR 1,791 million in FY25. Operating cash flow was positive at INR 772 million after a negative INR 2,109 million the year before. Borrowings fell from INR 20,337 million to INR 13,323 million over the year. In diagnostics, the annual report says Thyrocare offers 1,275 tests through 41 labs and has more than 10,800 active franchise partners. Goodwill of INR 35,133 million sits on the balance sheet, mostly from past acquisitions. The board is led by Rahul Guha as Managing Director and CEO, with co-founder Siddharth Shah as Vice Chairman and Aditya Puri as non-executive Chairman. TPG is among the investors with a board nominee. API Holdings has not listed its shares. Unlisted shares of a company like this are dealt off-market between private parties, so the price shown on this page is indicative, currently ₹6.75 per share with a lot size of 10000. It is not an exchange price. There is no linked IPO on IPO Guru yet.